Loading...
•
Mar 31, 2025
Vericel Q1 2025 Earnings Report
Estimated Revenue:$53.6M
+9.7% YoY
Estimated EPS:-$0.129
18.8% YoY
Key Takeaways
Vericel reported record first quarter MACI and total revenue, driven by continued strength in MACI Arthro launch. The company reaffirmed full-year revenue guidance and raised profitability guidance.
Total net revenue for the first quarter of 2025 was $52.6 million, an increase from $51.3 million in the prior year.
MACI net revenue grew by 15% to $46.3 million, representing a record first quarter for the product.
The company achieved a gross margin of 69% in the first quarter.
Vericel ended the quarter with approximately $162 million in cash, restricted cash, and investments, and no debt.
Revenue by Segment
Forward Guidance
Vericel reaffirmed full-year 2025 total revenue guidance with expected growth of 20% to 23% and raised full-year profitability guidance to a gross margin of 74% and adjusted EBITDA margin of 26%. Second quarter total revenue growth is expected to be 22% to 25%.
Positive Outlook
- Reaffirmed full-year total revenue growth guidance of 20% to 23%.
- Raised full-year profitability guidance to gross margin of 74%.
- Raised full-year profitability guidance to adjusted EBITDA margin of 26%.
- Expected second quarter total revenue growth of 22% to 25%.
- Company is well-positioned for continued high revenue and profit growth in 2025 and beyond.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...